Has Haritha Pabbathi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,612 in general payments to Haritha Pabbathi, MD across 380 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Haritha Pabbathi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Haritha Pabbathi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Haritha Pabbathi, MD

Hematology & Oncology · Griffin, GANPI 1215000989

Payments from drug & device makers

$18,612in general payments, 2019–2025

Across 380 payments — averaging $48.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$6K
AstraZeneca$5K
Novartis$2K
Merck$606
Daiichi Sankyo Inc.$606
Bayer$323
plus $4K from 45 others

What the payments were for

Consulting fees$5,54530%
Speaking & faculty fees$5,60030%
Food & beverage$6,98838%
Education$4793%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer(2 entities)	39	$6,113
AstraZeneca(2 entities)	24	$4,986
Novartis	34	$1,689
Merck	37	$606
Daiichi Sankyo Inc.	14	$606
Bayer	18	$323
Taiho Oncology, Inc.	20	$308
Amgen	20	$287
Lilly USA, LLC	9	$271
Gilead	7	$256
Genentech USA, Inc.	18	$253
Stemline Therapeutics Inc.	5	$240
Incyte Corporation	6	$217
Takeda Pharmaceuticals U.S.A., Inc.	9	$213
Eisai Inc.	12	$199
Bristol Myers Squibb	10	$169
Johnson & Johnson	8	$152
GSK	8	$147
Puma Biotechnology, Inc.	7	$139
Exelixis Inc.	5	$135
AbbVie	5	$104
Geron Corporation	4	$100
Sanofi	5	$96
Beigene USA, Inc.	5	$83
Regeneron Healthcare Solutions, Inc.	3	$78
Sobi, Inc	1	$75
UCB, Inc.	3	$73
Beone Medicines USA, Inc.	3	$68
Kyowa Kirin, Inc.	4	$59
Array Biopharma Inc	8	$54
Ipsen Biopharmaceuticals, Inc	3	$45
Seagen Inc.	3	$40
Legend Biotech USA Inc.	2	$40
Astellas Pharma US Inc	2	$39
Deciphera Pharmaceuticals Inc.	2	$38
E.r. Squibb & Sons, L.L.C.	2	$28
Axsome Therapeutics, Inc.	1	$27
Jazz Pharmaceuticals Inc.	1	$26
Myriad Genetic Laboratories, Inc.	1	$25
Azurity Pharmaceuticals, Inc.	1	$22
Immunogen, Inc.	1	$22
Sumitomo Pharma America, Inc.	1	$21
G1 Therapeutics, Inc.	1	$19
Tempus AI, Inc	1	$19
Servier Pharmaceuticals LLC	1	$18
Nuvation Bio Inc.	1	$17
Agios Pharmaceuticals, Inc.	1	$15
Novocure Inc.	1	$14
Mirati Therapeutics, Inc.	1	$14
Coherus Oncology, Inc.	1	$12
Sanofi-aventis U.S. LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TALZENNA$3,100
IBRANCE$2,500
PIQRAY$1,080
LYNPARZA$125
Trodelvy$124
Orserdu$124
Enhertu$124
VERZENIO$123

How this compares

$18,612 in reported general payments places this provider in the 60th percentile of 370 hematology & oncology providers in Georgia.

See all hematology & oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$25,150

Medicare patients

250

Services billed

1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	218	$5,476
Tamoxifen Citrate	76	$1,772
Anastrozole	63	$1,302
Exemestane	17	$1,088
Fentanyl	13	$634
Duloxetine Hcl	14	$220
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	19	$174

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Griffin

Mehmet BilenAtlanta$21.7M
Steven McCuneMarietta$19.5M
Ajay NookaAtlanta$19.3M
Olatunji AleseAtlanta$15.5M
Jonathon CohenAtlanta$8.7M
Ticiana LealAtlanta$6.1M
Amelia ZelnakCumming$4.4M
Conor SteuerAtlanta$4.4M
Anthony HunterAtlanta$4.3M
Robert BrownAtlanta$4.2M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →